About us

AtG is a spin-off company from the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) in Barcelona specialized in the discovery and development of new therapeutic technology for cancer resistance to improve the lives of cancer patients.

Our goal is to change the traditional model of trial and error that has been followed so far in oncology management

Project infographic


Anti-angiogenic resistance has become a clinical problem for cancer patients. 


There is a shortage of effective treatments against anti-angiogenic resistance and no biomarkers to predict treatment response. 


AtG is developing a new drug to prevent anti-angiogenics resistance with its patient selection biomarker to identify who will benefit from the treatment. 



The science is based on our unique ability to design and develop strategies that selectively target and eliminate cancer cells resistant to anti-angiogenic therapy and a plasma biomarker able to identify who would be benefit from the target inhibition.

Find out more about our technology


The novelty and the potential impact of the AtG project has been recognized by several entities at a national and international level.

European Research Council (ERC)

Learn more